Zev M Nakamura
Overview
Explore the profile of Zev M Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura Z, Deal A, Yopp J, Wardell A, Manning M, Pak P, et al.
Psychooncology
. 2025 Jan;
34(1):e70072.
PMID: 39763133
Objective: To evaluate the feasibility, acceptability, and preliminary efficacy of Families Addressing Cancer Together (FACT), a web-based, individually tailored, psychoeducational intervention for parents with cancer to improve illness-related communication with...
2.
Kent E, Tan K, Nakamura Z, Kovacs J, Gellin M, Deal A, et al.
Cancer Med
. 2024 Sep;
13(17):e70187.
PMID: 39234997
Introduction: Rural cancer caregivers experience obstacles in accessing services, obtaining respite, and ensuring their care recipients receive quality care. These challenges warrant opportunities to participate in evidence-based behavioral intervention trials...
3.
Artese A, Zhou X, Tometich D, Small B, Ahles T, Ahn J, et al.
J Natl Cancer Inst
. 2024 Aug;
116(12):2009-2021.
PMID: 39107910
Background: Physical activity can improve cognition; however, little is known regarding the relationships between longitudinal objectively measured physical activity, cognition, and inflammation in older breast cancer survivors. Methods: Older (aged...
4.
Nakamura Z, Ali N, Crouch A, Dhillon H, Federico A, Gates P, et al.
Semin Oncol Nurs
. 2024 Jul;
40(5):151696.
PMID: 39048409
Objectives: This systematic review (PROSPERO CRD42021275421) synthesized evidence on the efficacy of cognitive rehabilitation on cognitive and functional outcomes in adult cancer survivors. Methods: Articles were identified though PubMed/MEDLINE, EMBASE,...
5.
Mandelblatt J, Dage J, Zhou X, Small B, Ahles T, Ahn J, et al.
J Natl Cancer Inst
. 2024 May;
116(9):1495-1507.
PMID: 38788675
Purpose: We evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors. Methods: We included survivors aged 60-90 years with primary stage...
6.
McDeed A, Van Dyk K, Zhou X, Zhai W, Ahles T, Bethea T, et al.
JNCI Cancer Spectr
. 2024 Mar;
8(2).
PMID: 38556480
Purpose: Cancer survivors commonly report cognitive declines after cancer therapy. Due to the complex etiology of cancer-related cognitive decline (CRCD), predicting who will be at risk of CRCD remains a...
7.
Nakamura Z, Small B, Zhai W, Ahles T, Ahn J, Artese A, et al.
J Cancer Surviv
. 2023 Nov;
PMID: 37924476
Purpose: To identify trajectories of depressive symptoms in older breast cancer survivors and demographic, psychosocial, physical health, and cancer-related predictors of these trajectories. Methods: Recently diagnosed nonmetastatic breast cancer survivors...
8.
Henneghan A, Van Dyk K, Zhou X, Moore R, Root J, Ahles T, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(1):139-145.
PMID: 37330430
Purpose: The Patient-Reported Outcome Measurement Information System Cognitive Function Short Form 8a (PROMIS Cog) could provide a shorter, useful alternative to the often used Functional Assessment of Cancer Therapy -...
9.
Rentscher K, Bethea T, Zhai W, Small B, Zhou X, Ahles T, et al.
Cancer
. 2023 Jun;
129(17):2741-2753.
PMID: 37259669
Background: Cancer and its treatments may accelerate aging in survivors; however, research has not examined epigenetic markers of aging in longer term breast cancer survivors. This study examined whether older...
10.
Mandelblatt J, Small B, Zhou X, Nakamura Z, Cohen H, Ahles T, et al.
Cancer
. 2023 Apr;
129(15):2409-2421.
PMID: 37096888
Background: Immune activation/inflammation markers (immune markers) were tested to explain differences in neurocognition among older breast cancer survivors versus noncancer controls. Methods: Women >60 years old with primary breast cancer...